# EDGAR Filing Document

**Accession Number:** 0001023549
**File Stem:** 0001213900-26-050305
**Filing Date:** 2026-4
**Character Count:** 6665
**Document Hash:** bc45183de8012ac9c8f3e9cf20574a08
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-050305.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001213900-26-050305

**CONFORMED SUBMISSION TYPE**: NT 20-F

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**EFFECTIVENESS DATE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** XTL BIOPHARMACEUTICALS LTD
- **CENTRAL INDEX KEY:** 0001023549
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3

**FILING VALUES:**
- **FORM TYPE:** NT 20-F
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36000
- **FILM NUMBER:** 26926274

**BUSINESS ADDRESS:**
- **STREET 1:** XTL BIOPHARMACEUTICALS LTD
- **STREET 2:** C/O ALSTON & BIRD LLP, 90 PARK AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016
- **BUSINESS PHONE:** 972 9 955 7080

**MAIL ADDRESS:**
- **STREET 1:** 26 BEN-GURION ST.
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5112001

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

*(Check one):* ◻ Form 10-K ⌧ Form 20-F ◻ Form 11-K <br> ◻ Form 10-Q ◻ Form 10-D ◻ Form N-CEN ◻ Form N-CSR

For Period Ended: **<u>December 31, 2025</u>**

◻ Transition Report on form 10-K

◻ Transition Report on Form 20-F

◻ Transition Report on Form 11-K

◻ Transition Report on Form 10-Q

For the Transition Period Ended:_____________________________

*Read Instruction (on back page) Before Preparing Form. Please Print or Type.*<br> **Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**<br>

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:________________________________

**PART I ─ REGISTRANT INFORMATION**

XTL Biopharmaceuticals Ltd.

Full Name of Registrant

Former Name if Applicable

26 Ben Gurion St.

Address of Principal Executive Office *(Street and Number)*

Ramat Gan, Israel, 5112001

City, State and Zip Code

**PART II ─ RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

---

| | | |
|:---|:---|:---|
| ☒ | (a) | The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;<br>|
| ☐ | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and<br>|
| ☐ | (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

---

**PART III ─ NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

XTL Biopharmaceuticals Ltd. (the "Company") is currently facing an unprecedented challenge, rare for public issuers, and therefore unable to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 (the "Form 20-F") within the prescribed period due to the liquidation proceedings of the Company's wholly owned subsidiary, The Social Proxy Ltd. (the "Subsidiary"), and the lack of operational and financial data regarding the Subsidiary required to finalize its audited financial statements and other disclosures in the Form 20-F. The Company expects to file its Annual Report on Form 20-F once the operational and financial information regarding the Subsidiary becomes available or after receiving court and/or authorities' guidance allowing it not to include such information in the Form 20-F.

**PART IV ─ OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

<u>Noam Band</u> <u>972</u> <u>3-6116600</u> <br> (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

Yes ⌧ No ◻

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ◻ No ⌧

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**Forward-Looking Statements**

This notification includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The word "expects," "anticipates" and similar terms and phrases are used in this notification to identify forward-looking statements. Risks, uncertainties and assumptions that could affect the Company's forward-looking statements include, among other things, any changes to our anticipated financial results as a result of our independent registered public accounting firm completing its audit of the Company's financial statements, the ability of us and our auditors to confirm information or data identified in the review, our ability to complete and file future periodic filings with the SEC on a timely basis and other risks and uncertainties discussed more fully in the Company's filings with the SEC. Unless required by law, the Company expressly disclaims any obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

<u>XTL Biopharmaceuticals Ltd. </u> <br> (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | April 30, 2026 | By: | /s/ Noam Band |
|  |  | Name: | Noam Band |
|  |  | Title: | Chief Executive Officer |

---